Dark

Check out our Dark Pool Levels

FIXX
Homology Medicines, Inc. Common Stock
stock NASDAQ

Inactive

Mar 25, 2024

16.82USD-94.402%(-283.72)22,304

Pre-market

0.00USD-100.000%(-300.54)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 28, 2022

02:30AM EST Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business GlobeNewswire Inc

Nov 16, 2021

06:01AM EST Chardan Capital Maintains Buy on Homology Medicines, Lowers Price Target to $25 Benzinga

Nov 15, 2021

11:53AM EST Looking Into Homology Medicines's Return On Capital Employed Benzinga

10:56AM EST Homology Medicines Q2 EPS $(0.54) Beats $(0.59) Estimate, Sales $2.19M Beat $430.00K Estimate Benzinga

07:10AM EST - Achieved Goal of Three Clinical Programs Across Gene Therapy and Gene Editing Technology Platform This Year - GlobeNewswire Inc

Nov 3, 2021

08:29AM EDT Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in the following virtual conferences: GlobeNewswire Inc

Oct 21, 2021

07:00AM EDT - Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - GlobeNewswire Inc

Oct 20, 2021

08:31AM EDT Homology Medicines Highlights Presentation Of Data Supporting Clinical Programs In MPS II And PKU, Including Nonclinical And Patient-Focused Research, At American Society Of Human Genetics Meeting Benzinga

08:30AM EDT - Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials - GlobeNewswire Inc

Oct 18, 2021

08:48AM EDT Homology Medicines Reports Initiation Of Trial For HMI-203 Gene Therapy Candidate For Adults With Hunter Syndrome Benzinga

08:30AM EDT - juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome - GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal Benzinga

Oct 12, 2021

04:08PM EDT Homology Medicines Announces World's First Gene Editing Clinical Trial for PKU Benzinga

04:05PM EDT - IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - GlobeNewswire Inc

Aug 12, 2021

05:07PM EDT Homology Medicines Q2 EPS $(0.54) Up From $(0.78) YoY, Sales $2.19M Up From $567.00K YoY Benzinga

04:05PM EDT - On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021- GlobeNewswire Inc

Aug 4, 2021

08:30AM EDT Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences: GlobeNewswire Inc

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 13, 2021

07:00AM EDT - Data From New GTx-mAb Platform Demonstrated Proof of Principle for AAVHSCs to Deliver One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model - GlobeNewswire Inc

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

04:56PM EDT Homology Medicines Q1 EPS $(0.02) Up From $(0.78) YoY, Sales $29.30M Up From $588.00K YoY Benzinga

May 3, 2021

08:11AM EDT Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting Benzinga

08:00AM EDT - Data Showed AAVHSCs Edited Human Retinal Cell Types Across Two Targets - GlobeNewswire Inc

Apr 28, 2021

08:16AM EDT Homology Medicines Announces New Approach To 'Leverage AAVHSC Platform By Delivering One-Time In Vivo Gene Therapy To Produce Antibodies In Humanized Murine Model' Benzinga

08:00AM EDT - Proof of Concept Data for New GTx-mAb Platform to Be Featured at ASGCT Along With Presentations From Multiple Programs - GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 19, 2021

10:18AM EDT Stocks That Hit 52-Week Lows On Monday Benzinga

Apr 14, 2021

08:30AM EDT - Data From Companys PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations - GlobeNewswire Inc

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 12, 2021

08:41AM EDT Homology Medicines Reports Tim Kelly Promoted To COO Benzinga

08:30AM EDT -Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership - GlobeNewswire Inc

Apr 8, 2021

08:47AM EDT Homology Medicines Inc Files Prospectus Supplement Related To Offering 6.6M Shares Of Co.'s Common Stock Benzinga

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Apr 7, 2021

03:12PM EDT Mid-Afternoon Market Update: Dow Falls 25 Points; Homology Medicines Shares Slide Benzinga

12:54PM EDT Mid-Day Market Update: Crude Oil Down Over 1%; FibroGen Shares Plummet Benzinga

09:49AM EDT Mid-Morning Market Update: Markets Mostly Higher; RPM Earnings Beat Views Benzinga

08:53AM EDT Homology Medicines Prices Offering For Proceeds ~$50M Benzinga

08:52AM EDT Homology Medicines Announces Pricing of Public Offering of Common GlobeNewswire Inc

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

06:51AM EDT A Peek Into The Markets: US Stock Futures Edge Higher Ahead of Fed Minutes Benzinga

Apr 6, 2021

04:20PM EDT Homology Medicines Announces Proposed Public Offering Of $50M Of Common Stock Benzinga

04:19PM EDT Homology Medicines Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Mar 11, 2021

04:47PM EST Homology Medicines Filing Shows Registration For $350M Mixed Securities Shelf Offering Benzinga

04:34PM EST Homology Medicines Q4 EPS $(0.62) Down From $(0.55) YoY, Sales $1.00M Up From $563.00K YoY Benzinga

04:10PM EST - Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End - GlobeNewswire Inc

Mar 2, 2021

01:23PM EST Stifel Initiates Coverage On Homology Medicines with Hold Rating, Announces Price Target of $14 Benzinga

Mar 1, 2021

09:51AM EST Homology Medicines Regains Global Rights To Novartis Ophthalmology Program Benzinga

07:31AM EST Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform Benzinga

07:30AM EST - Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - GlobeNewswire Inc

Feb 25, 2021

08:00AM EST Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences: GlobeNewswire Inc

Feb 8, 2021

02:52PM EST Homology Medicines Announces First Presentation Of Data With HMI-203 In Vivo Gene Therapy Development Candidate For Hunter Syndrome Benzinga

02:51PM EST - IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - GlobeNewswire Inc

Jan 12, 2021

07:07AM EST Pfizer Inc. (PFE) announced Tuesday that it invested a total of $120 million in four clinical-stage biotech companies during the second half of 2020 as part of the Pfizer Breakthrough Growth Initiative (PBGI). RTTNews

06:50AM EST Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative Benzinga

Jan 6, 2021

08:07AM EST Homology Medicines Announces Plans For Three Clinical Programs In 2021 Spanning Phenylketonuria And Hunter Syndrome Benzinga

08:00AM EST - Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - GlobeNewswire Inc

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Nov 19, 2020

04:19PM EST Homology Medicines 13G Filing From Pfizer Shows 9.9% Stake In Co. Benzinga

Nov 10, 2020

03:05PM EST Hagens Berman urges Homology Medicines, Inc. (NASDAQ FIXX) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims. GlobeNewswire Inc

08:24AM EST Homology Medicines Spokesperson Says Co Expects To Use Pfizer Investment For Ongoing, Planned Phenylketonuria Clinical Trials, Central Nervous System Programs Benzinga

Nov 9, 2020

04:27PM EST Homology Medicines Q3 EPS $(0.62) Up From $(0.67) YoY, Sales $567.00K Up From $441.00K YoY Benzinga

04:05PM EST - Based on Positive Data,Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase - GlobeNewswire Inc

08:10AM EST Homology Medicines Announces $60 Million Equity Investment From Pfizer Inc. Benzinga

08:09AM EST Homology Medicines Reports $60M Equity Investment From Pfizer: Pfizer To Buy 5M Shares At $12/Share Benzinga

08:00AM EST Homology Medicines Announces $60 Million Equity Investment from GlobeNewswire Inc

Nov 6, 2020

11:46AM EST Homology Medicines Reports Presentation Of Positive Data From Dose-Escalation Phase Of pheNIX Gene Therapy Trial For Adults With Phenylketonuria Benzinga

11:40AM EST Homology Medicines Announces Presentation of Positive Data from GlobeNewswire Inc

Oct 26, 2020

05:37PM EDT Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the investigations can be found at the links provided. GlobeNewswire Inc

04:42PM EDT CORRECTION: Comfort Systems USA Ticker Is 'FIX' Benzinga

Oct 22, 2020

08:32AM EDT Homology Medicines Reports New In Vivo Gene Therapy Development Program For Treatment Of Mucopolysaccharidosis Type II Benzinga

08:30AM EDT HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data ShowedImprovements in Key Disease Biomarkers GlobeNewswire Inc

Oct 14, 2020

05:28PM EDT Hagens Berman urges Homology Medicines, Inc. (NASDAQ FIXX) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims. GlobeNewswire Inc

Oct 12, 2020

11:47PM EDT Pomerantz LLP is investigating claims on behalf of investors of Homology Medicines, Inc. (Homology or the Company) (NASDAQ: FIXX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

05:00PM EDT Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Homology Medicines (NASDAQ: FIXX) on behalf of Homology stockholders. Our investigation concerns whether Homology has violated the federal securities laws and/or engaged in other unlawful business practices. GlobeNewswire Inc

Oct 8, 2020

09:44PM EDT Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud PR Newswire

Sep 18, 2020

09:00AM EDT Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences: GlobeNewswire Inc

Aug 11, 2020

11:25AM EDT HC Wainwright & Co. Maintains Buy on Homology Medicines, Lowers Price Target to $30 Benzinga

10:25AM EDT Shares of Homology Medicines, Inc. (FIXX) are falling more than 11% Tuesday morning after the company missed second-quarter earnings. RTTNews

Aug 10, 2020

04:30PM EDT Homology Medicines Q2 EPS $(0.78) Down From $(0.61) YoY, Sales $567.00K Up From $392.00K YoY Benzinga

04:05PM EDT Homology Medicines Reports Second Quarter 2020 Financial Results GlobeNewswire Inc

Jul 21, 2020

08:06AM EDT Homology Medicines Names Jeff Poulton To Board RTTNews

08:01AM EDT - Executive with Extensive Rare Disease Expertise in Global Finance andCommercial Operations - GlobeNewswire Inc

Share